Follicle Stimulating Hormone Market Growth, Trends 2024-2033

Overview and Scope

Follicle-stimulating hormone is a hormone that the pituitary gland secretes and is involved in sexual maturation and reproduction. It has an impact on how well the testicles and ovaries work. Follicle-stimulating hormone assists in regulating both the ovaries’ egg production and the menstrual cycle.

Sizing and Forecast

The follicle stimulating hormone market size has grown strongly in recent years. It will grow from $1.94 billion in 2023 to $2.05 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to increased prevalence of hormonal disorders, growing demand for fertility treatment, expansion of fsh indications, market entry of new fsh products, growing demand for safe and effective contraceptive options.

The follicle stimulating hormone market size is expected to see steady growth in the next few years. It will grow to $2.49 billion in 2028 at a compound annual growth rate (CAGR) of 5.0%. The growth in the forecast period can be attributed to widening therapeutic applications, rising demand for combination therapy, growing need for effective contraceptive options, aging population and related healthcare needs, market expansion in key regions. Major trends in the forecast period include advanced biosimilar fsh products, regulatory approvals and market access, technological advancements in fsh production and delivery, growing need for effective contraceptive options.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/follicle-stimulating-hormone-global-market-report

Segmentation & Regional Insights

The follicle stimulating hormone market covered in this report is segmented –

1) By Type: Recombinant FSH, Urinary FSH

2) By Application: Infertility Treatment, Assisted Reproductive Technology (ART), Other Applications

3) By End-Users: Infertility Center, Hospitals, Other End-Users

North America was the largest region in the follicle stimulating hormone market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the follicle stimulating hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12486&type=smp

Major Driver Impacting Market Growth

The increasing prevalence of infertility is expected to propel the growth of the follicle-stimulating hormone market. Infertility is a condition affecting the male or female reproductive system that is indicated by the inability to conceive after 12 months or longer of frequent, unprotected sexual contact. Follicle-stimulating hormone encourages the development of eggs in the ovaries and aids in regulating the menstrual cycle in females. It promotes testicular growth in men and aids in producing a protein essential for male fertility by promoting the development of healthy sperm cells. For instance, in April 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, infertility affected around 1 in 6 adults worldwide, or about 17.5% of the adult population. Furthermore, in October 2023, according to the Australian Bureau of Statistics, an Australia-based self-governing constitutional organization entrusted with gathering and analyzing information and making fact-based recommendations to the national, state, and territory governments, there were 300,684 recorded births in 2022, a 3% drop from 2021. The overall fertility rate for all Australian women was 1.63 births per woman. Therefore, the increasing prevalence of infertility is driving the growth of the follicle-stimulating hormone market.

Key Industry Players

Major companies operating in the follicle stimulating hormone market report are Pfizer Inc., Novartis AG, Abbott Laboratories, Sanofi S.A., Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Cipla Ltd., Ferring Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Livzon Pharmaceutical Group Inc., Emcure Pharmaceuticals Ltd., LG Chem’s life sciences, IBSA Group, Bharat Serums and Vaccines Limited, Nihon Kohden Corp., Anhui Anke Biotechnology Group Co. Ltd., Taj Pharmaceuticals Ltd., Genpharm Inc., Cadwell Laboratories Inc., Creative BioMart, Electrical Geodesics Inc., Lee Biosolutions Inc., Trumac Healthcare, Midas Pharma GmbH, Biogenix Inc. Pvt. Ltd., Shanghai Techwell Biopharmaceutical Co. Ltd.

The follicle stimulating hormone market report table of contents includes: